ALS

First targeted therapy for rare genetic ALS succeeds in Phase 3 trial

Ionis Pharmaceuticals and Otsuka Pharmaceutical announced on Tuesday that ulefnersen, an investigational RNA-targeted therapy, met the primary endpoint of the Phase III FUSION trial in patients with a rare genetic form of amyotrophic lateral sclerosis, marking a first for this…

Stanford finds human brain is two organs fused by evolution

A study published in Nature Neuroscience on September 18 has upended a foundational assumption in neuroscience: the human brain, long treated as a single organ with a shared developmental origin, appears to be two ancient nervous systems fused together over…

Study finds human brain develops from two separate organs, not one

The human brain is not the singular organ scientists long assumed it to be. A study published Friday in Nature Neuroscience by a Stanford Medicine-led research team reveals that the brain develops from two separate populations of progenitor cells, overturning…